The Rise in ADHD and Autism Diagnoses in Children in the United States
More children in the United States are being diagnosed with autism and ADHD than at any point on record, and the pace of that increase has surprised even the researchers who track it. According to the CDC’s most recent Autism and Developmental Disabilities Monitoring Network report, roughly 1 in 31 eight-year-olds in the U.S. — about 3.2% — is now identified with autism spectrum disorder, up from 1 in 150 when the agency began tracking the condition among children born in the early 1990s. ADHD has followed a similar trajectory, with national survey data showing several million children currently carrying the diagnosis.
Long Term Outcomes in Children With ADHD and the Importance of Early Intervention
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common conditions affecting children, and it can have long-lasting effects if not recognized and supported early. While many parents focus on immediate school or behavior concerns, research shows that early intervention can significantly influence a child’s academic, social, and emotional development.
Demographic Differences in ADHD Diagnosis Trends Across the U.S.
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most commonly diagnosed conditions in children and adolescents in the United States. While it affects millions of young people, research and national data show that how often and how ADHD is diagnosed varies by age, gender, race, and geographic location. Understanding these demographic differences can help families, educators, and clinicians recognize patterns in diagnosis and address gaps in support.
ADHD Prevalence in Children and What They Reveal
Attention-Deficit/Hyperactivity Disorder (ADHD) affects millions of children worldwide, making it one of the most common neurodevelopmental conditions. In the United States, recent estimates indicate that approximately 11% of children aged 4–17 have received an ADHD diagnosis at some point.
The role of omega-3 derived resolvins in arthritis
Omega-3 polyunsaturated fatty acids (PUFAs) are known to alleviate joint stiffness and pain in rheumatoid arthritis patients. However, the mechanisms by which omega-3s exert their beneficial effects has not been fully explored. Herein we discuss a novel class of bioactive lipid mediators, which are enzymatically biosynthesized in vivo from omega-3 eicosapentaenoic acid (EPA) and , docosahexaenoic acid (DHA), termed resolvins.